MAGNETIC MEASUREMENT OF HUMAN IRON STORES

拟议中的研究将使用生物磁共振测量法-一种方法 由我们的实验室引入和开发-测量肝脏储存 铁代谢紊乱患者的铁浓度。 在 目前，非侵入性磁性测定和 通过活组织检查获得的肝组织的化学分析是定量的 当身体铁储存正常或增加时，相当于。 选用我们的 计算机增强，双通道，超导量子干涉 设备（SQUID）温度计，计算机控制整个测量 程序并自动计算肝脏铁浓度。 在 效果，电导法提供了一种自动化的，安全的， 肝脏铁蛋白和含铁血黄素铁的非侵入性磁性“活检”， 深受患者欢迎。 在铁超载患者中， 研究可以准确、直接、可靠和重复地测量 肝铁是不可能与任何其他可用的方法。 在临床上，肝脏磁测量将用于检测 和连续监测铁超载患者。 遗传性 血色素沉着症，磁性测定肝脏铁储备， 在发病早期阶段识别受影响的个体， 铁状态的常规间接测量（血清、铁蛋白、转铁蛋白 饱和）可能是不可靠的， 放血疗法 磁性测量为快速测量提供了一种新的手段。 确定治疗程序的有效性（螯合， 输血）中的输血性铁超负荷（重型地中海贫血，其他 难治性贫血）。 使用新的双通道仪器进行的研究 已经提供了新的定量见解， 处方最佳个性化螯合治疗方案， 输血铁超载。 其他的研究是针对评估 镰状细胞性贫血患者输血时铁的毒性 预防卒中复发和铁负荷性贫血患者 非输血性铁过量 在迟发性皮肤卟啉症中， 临床表现与肝脏铁含量的关系将是 在静脉切开术治疗期间进行评估。 铁的普遍性和重要性 酒精性肝硬化和需要慢性 血液透析将在我们的医院人群中进行检查。 我们的目标 研究的目的是直接确定 铁储备水平和疾病的病理生理表现 铁的代谢。

The proposed research will use biomagnetic susceptometry - a method introduced and developed by our laboratories - to measure hepatic storage iron concentrations in patients with disorders of iron metabolism. At present, the results of non-invasive magnetic determinations and of the chemical analysis of hepatic tissue obtained by biopsy are quantitatively equivalent when body iron stores are normal or increased. With our new computer-enhanced, dual channel, superconducting quantum-interference device (SQUID) susceptometer, a computer controls the entire measurement procedure and automatically calculates the hepatic iron concentration. In effect, the susceptometric method provides an automated, safe, and non-invasive magnetic "biopsy" of liver ferritin and hemosiderin iron that is well accepted by patients. In patients with iron overload, magnetic studies permit accurate, direct, reliable, and repeated measurements of hepatic iron that are not possible with any other available method. Clinically, hepatic magnetic measurements will be used for the detection and serial monitoring of patients with iron overload. In hereditary hemochromatosis, magnetic determinations of hepatic iron stores can identify affected individuals at an early precirrhotic stage when conventional indirect measures of iron status (serum, ferritin, transferrin saturation) may be unreliable and make possible early, preventive phlebotomy therapy. Magnetic measurements provide a new means for rapidly determining the effectiveness of treatment programs (chelation, transfusion) in transfusional iron overload (thalassemia major, other refractory anemia). Studies using the new dual channel instrument have already provided new quantitative insights that make possible the prescription of optimal individualized chelation regimens for patients with transfusional iron overload. Other studies are directed toward evaluating the toxicity of iron in patients with sickle cell anemia transfused for the prevention of recurrent stroke and in patients with iron-loading anemias with non-transfusional iron excess. In porphyria cutanea tarda, the relationship of clinical manifestations to hepatic iron content will be assessed during phlebotomy therapy. The prevalence and magnitude of iron overload in alcoholic cirrhosis and in patients requiring chronic hemodialysis will be examined in our hospital population. The goal of our studies is to determine directly the quantitative relationship between the level of iron stores and the pathophysiologic manifestations of disorders of iron metabolism.